SCHEMBL7092226

SCHEMBL7092226

O=C(CC(CC(=O)OCl)c1ccccc1)OCl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
GABBR2 O75899 1/20 0.48
GABBR1 Q9UBS5 1/20 0.48
CYP2D6 P10635 2/20 0.47
CYP1A2 P05177 1/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ATM Q13315 1/20 0.44
FNTA P49354 3/20 0.41
FNTB P49356 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41
SRC P12931 1/20 0.40
F2 P00734 1/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9836455 0.82 ALDH1A1 (0.51) ALDH1A1GABBR2GABBR1CYP2D6CYP1A2
SCHEMBL7334843 0.81 HTT (0.42) ALDH1A1GABBR2GABBR1NPSR1MAPT
SCHEMBL7995142 0.80 ALDH1A1 (0.67) ALDH1A1GABBR2GABBR1CYP2D6CYP1A2
SCHEMBL9541616 0.78 GABBR2 (0.61) ALDH1A1GABBR2GABBR1CYP2D6CYP1A2
SCHEMBL657290 0.78 GABBR2 (0.61) ALDH1A1GABBR2GABBR1CYP2D6CYP1A2
SCHEMBL232194 0.77 F2 (0.59) ALDH1A1GABBR2GABBR1CYP2D6CYP1A2
SCHEMBL3056242 0.77 GABBR2 (0.53) ALDH1A1GABBR2GABBR1CYP2D6CYP1A2
SCHEMBL503819 0.76 GABBR2 (0.76) GABBR2GABBR1CYP2D6CYP1A2PKM
SCHEMBL12268202 0.76 ALDH1A1 (0.61) ALDH1A1GABBR2GABBR1MAPTL3MBTL1
SCHEMBL1811811 0.76 ALDH1A1 (0.61) ALDH1A1GABBR2GABBR1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 ALDH1A1 33/4885GABBR2 3147/4885GABBR1 3056/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 ALDH1A1 63/4885GABBR2 3916/4885GABBR1 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.